Loading...
Bilateral Trade Intelligence · $2.7K Total Trade · 5 Foreign Suppliers · 2 Indian Buyers · DGFT Verified · Updated March 2026
India imported $2.7K worth of pharmaceutical formulations from Algeria across 9 verified shipments, from 5 foreign suppliers to 2 Indian buyers. The top suppliers are M/S. BIOPHARM SPA ($2.3K) and GROUP INDUSTRIEL SAIDAL SPA ($213). The leading products are Pazopanib ($2K) and Plasma ($213). Average shipment value: $298.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Pazopanib | $2.3K | 86.5% |
| 2 | Plasma | $213 | 7.9% |
| 3 | Lenalidomide | $103 | 3.8% |
| 4 | Imatinib | $46 | 1.7% |
India imports 4+ pharmaceutical formulations from Algeria with a combined trade value of $2.7K. Key products include Pazopanib ($2K), Plasma ($213), Lenalidomide ($103), Imatinib ($46). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 9 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Algeria, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Algeria buyers, regulatory requirements, and logistics for that specific product corridor. Products include Pazopanib ($2K), Plasma ($213), Lenalidomide ($103), Imatinib ($46) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
export finished formulations to Algeria. Leading exporters include . The top exporter accounts for 86.2% of total India–Algeria pharma exports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Algeria and India has experienced modest activity from 2022 to 2026. During this period, India imported a total of $3,000 USD worth of finished pharmaceutical formulations from Algeria, distributed across nine shipments. The average shipment value stood at approximately $298 USD. This limited trade volume indicates a nascent yet potentially growing relationship in the pharmaceutical sector between the two nations.
The primary products imported include Pazopanib, Plasma, Lenalidomide, and Imatinib, with Pazopanib accounting for 86.5% of the total import value. The involvement of five Algerian suppliers and two Indian buyers suggests a developing trade network, albeit on a small scale. The regulatory oversight by India's Central Drugs Standard Control Organisation (CDSCO) and Algeria's National Drug Regulatory Authority (WHO-GMP) underscores the commitment to maintaining quality and safety standards in this trade corridor.
Algeria's contribution to India's pharmaceutical imports remains minimal, with a total import value of $3,000 USD over the past four years. This positions Algeria as a minor player in India's broader pharmaceutical import landscape. The imports predominantly consist of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicating a focus on ready-to-use products rather than active pharmaceutical ingredients (APIs) or raw materials.
2 companies in Algeria import pharmaceutical formulations from India. Top buyers include Cohance Lifesciences Limited, Indiglobal Labs Private Limited, . The largest buyer accounts for 92.1% of India–Algeria pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, there have been no significant policy changes by the CDSCO or notable trade agreements between India and Algeria specifically targeting the pharmaceutical sector. The limited trade volume suggests that the pharmaceutical trade relationship remains underdeveloped, with potential for growth contingent upon strategic initiatives and enhanced bilateral cooperation.
Registration process, GMP requirements, import documentation
Algerian pharmaceutical companies seeking to export finished formulations to India must navigate the CDSCO registration process to ensure compliance with Indian regulatory standards. The process involves several key steps:
1. Online Registration: Applicants must visit the CDSCO Sugam portal and create an account by providing necessary details such as applicant type, username, password, and contact information.
2. Application Submission: After account activation, applicants submit the required application form, selecting the appropriate registration category and location.
3. Document Upload: Essential documents include:
4. Fee Payment: Payment of applicable registration fees is required.
5. Application Review: CDSCO reviews the application and may request additional information or clarification.
6. Approval: Upon satisfactory review, CDSCO grants the registration, allowing the product to be imported and marketed in India.
The entire process is conducted online, facilitating transparency and efficiency. It's crucial for Algerian companies to ensure all documents are accurate and complete to avoid delays. The timeline for approval can vary, but applicants are typically notified of the outcome via email.
India requires that foreign manufacturing sites adhere to stringent Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of imported pharmaceutical products. Algerian manufacturers must obtain GMP certification from recognized authorities, such as the World Health Organization (WHO), to demonstrate compliance with these standards. The CDSCO may conduct inspections of manufacturing facilities to verify adherence to GMP guidelines. Non-compliance can result in delays or rejection of the registration application.
To import pharmaceutical products into India, Algerian companies must provide comprehensive documentation, including:
Ensuring all documentation is accurate and complete is vital to facilitate smooth importation and distribution within India.
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Algeria to India are predominantly focused on specific therapeutic areas, with a significant emphasis on oncology treatments. Pazopanib, a drug used in cancer therapy, constitutes 86.5% of the total import value, highlighting the demand for specialized treatments not readily available in India. Other imported products include Plasma, Lenalidomide, and Imatinib, which are also utilized in cancer treatment regimens. This trend indicates a niche but critical role for Algerian pharmaceutical products in addressing specific medical needs within India.
Algerian pharmaceutical exports to India include innovator drugs and novel formulations, particularly in the oncology sector. The importation of specialized treatments like Pazopanib and Lenalidomide suggests that these products offer therapeutic benefits not readily available from domestic manufacturers. This underscores the importance of international collaborations in providing advanced medical solutions to meet India's diverse healthcare requirements.
The demand for pharmaceutical imports from Algeria to India is driven by several factors:
These factors collectively contribute to the sustained demand for Algerian pharmaceutical products in India.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
These tariffs are subject to periodic revisions and can impact the pricing and competitiveness of imported pharmaceutical products.
As of March 2026, there are no specific Free Trade Agreements (FTAs) between India and Algeria that offer preferential duty rates for pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations, but does not include specific provisions for pharmaceutical products between them. Bilateral negotiations may occur, but no significant agreements have been reported in the pharmaceutical sector.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and promotes access to affordable medicines. Compulsory licensing provisions allow the government to authorize the production of patented drugs without the consent of the patent holder under certain conditions, such as public health emergencies. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability and accessibility for the Indian population.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Algeria to India are typically transported via sea routes, with major ports such as Algiers and Oran serving as export points. The transit time for sea freight from Algeria to India varies depending on the specific ports of departure and arrival, but generally ranges from 20 to 30 days. Air freight options are also available, offering faster delivery times but at higher costs. The reliability of these routes is generally high, with established shipping lines and logistics providers facilitating the movement of goods.
Algeria's key export ports include Algiers and Oran, which are equipped to handle pharmaceutical shipments. In India, major import ports such
India exported pharmaceuticals worth $2.7K to Algeria across 9 verified shipments.
1. M/S. BIOPHARM SPA — $2.3K. 2. GROUP INDUSTRIEL SAIDAL SPA — $213. 3. SARL DEMOCEDES PHARMA ALGERIE — $87. Total: 5 suppliers.
1. COHANCE LIFESCIENCES LIMITED — $2.5K. 2. INDIGLOBAL LABS PRIVATE LIMITED — $213. 2 buyers total.
1. Pazopanib ($2.3K, 86.5%); 2. Plasma ($213, 7.9%); 3. Lenalidomide ($103, 3.8%); 4. Imatinib ($46, 1.7%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $2.7K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$298 per consignment across 9 shipments.
5 Indian companies. Largest: M/S. BIOPHARM SPA with $2.3K.
TransData Nexus covers 5 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 9 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5 Exporters
2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists